facts and figures 2008

Facts and Figures 2008Medicines and Health Care

The Norwegian Association of Pharmaceutical Manufacturers (LMI)

Facts and Figures 2008 – Medicines and Health Care

1.01 The number of marketing authorisations, active ingredients and medicines in Norway

0

1 000

2 000

3 000

4 000

5 000

6 000

7 000

8 000

9 000

Number omMANumber of medicinesNumber of active ingredients

200720062005200420032002

Source: The Norwegian Medicines Agency

Year

Num

ber

1 316 1 354 1 371 1 387 1 414 1 4491 396 1 507 1 6451 838 1 994

2 145

8 004

6 829

6 3926 046

5 303

4 562


1.02 New and withdrawn active ingredients

Year New active substancesWithdrawn active

ingredients

2000 36 *

2001 45 *

2002 48 *

2003 24 *

2004 29 12

2005 25 13

2006 47 20

2007 51 16


*Number not available


1.03 Pharmaceutical sales in Norway in the last few years, 2007-currency

10 000

11 000

12 000

13 000

14 000

15 000

16 000

17 000

18 000

19 000

20 000

20072006200520042003200220012000

Year

Mill

.NO

K

16 90016 55016 60016 450

15 35015 300

13 850

12 850

Source: LMI/Farmastat and Statistics Norway Figures in 2007-currency


1.04 Sales growth by value

-2%

0%

2%

4%

6%

8%

10%

12%

14%

Groth in fixed pricesNominal growth

20072006200520042003200220012000

Year

Per

cent

age

grow

th

Source: Statistics Norway - LMI/Farmastat

6,5%

11,4%11,8%

2,8%

7,5%

2,5%1,9%

3,0%

2,3%

-0,4%

0,9%

7,1%

0,4%

10,4%

8,1%

3,3%


1.05 Sales growth by volume (DDD)

0%

1%

2%

3%

4%

5%

6%

7%

8%

9%

200720062005200420032002200120001999

Sal

esgr

owth

DD

D

Source: LMI/Farmastat

Year

Growth measured by DDD

8,0%

6,2%

7,3%7,7%

3,4%

5,9%

4,5%4,1%

4,7%


1.06 The Norwegian pharmaceutical market by main therapeutic groups (ATC)

Sales PPP 2007,NOK Million

Growth2006-2007

Share of totalsales 2007

N Central nervous system 2 163,7 4,7 % 19,9 %

LAntineoplastic and immuno-modulatingagents

1 998,3 12,4 % 18,4 %

C Cardiovascular system 1 431,5 -4,9 % 13,2 %

A Alimentary and metabolism 1 141,6 -1,3 % 10,5 %

R Respiratory system 1 105,9 0,6 % 10,2 %

B Blood and bloodforming organs 671,6 6,4 % 6,2 %

G Urogenitals and sex hormones 579,2 4,4 % 5,3 %

J Systemic antiinfectives 557,2 3,1 % 5,1 %

M Musculo-skeletal system 327,8 -11,9 % 3,0 %

H Systemic hormones excl. sex hormones 274,9 3,1 % 2,5 %

S Sensory organs 235,1 0,5 % 2,2 %

D Dermatologicals 232,3 8,9 % 2,1 %

V Various 114,4 0,0 % 1,1 %

P Antiparasitic products 32,7 11,0 % 0,3 %

Total 10 866,1 2,9 % 100,0 %



1.07 The top 25 Pharmaceutical companies on the Norwegian market

Rank 2007(2006) Company

Total sales 2007PPP, NOK mill. Sales growth Market share

1 (1) Pfizer AS 932,6 -13,9 % 8,6 %

2 (2) AstraZeneca AS 873,0 10,2 % 8,0 %

3 (3) GlaxoSmithKline AS 731,9 -3,8 % 6,7 %

4 (10) Schering-Plough AS 584,5 46,5 % 5,4 %

5 (5) Novartis Norge AS 566,4 12,9 % 5,2 %

6 (6) Wyeth Norge 446,4 -6,0 % 4,1 %

7 (8) MSD (Norge) AS 435,1 1,7 % 4,0 %

8 (4) sanofi-aventis 430,5 -17,1 % 4,0 %

9 (9) Nycomed Pharma AS 417,6 0,0 % 3,8 %

10 (11) Roche Norge A/S 347,1 3,2 % 3,2 %

11 (7) *Farmagon AS 315,2 -32,4 % 2,9 %

12 (12) Eli Lilly Norge AS 314,8 9,5 % 2,9 %

13 (13) Novo Nordisk Scandinavia AS 264,3 2,4 % 2,4 %

14 (16) Abbott Norge as 254,8 7,8 % 2,3 %

15 (17) Weifa AS 252,6 7,9 % 2,3 %

16 (-) Bayer Schering Pharma 249,8 - 2,3 %

17 (15) J anssen-Cilag AS 240,0 -0,8 % 2,2 %

18 (14) Alpharma AS 228,2 -6,6 % 2,1 %

19 (-) Bristol-Myers Squibb Norway Ltd 174,8 - 1,6 %

20 (20) Boehringer Ingelheim Norway KS 168,0 11,2 % 1,5 %

21 (22) H. Lundbeck A/S 154,9 13,8 % 1,4 %

22 (-) Merck Serono 144,1 - 1,3 %

23 (19) ratiopharm AS 134,3 -15,8 % 1,2 %

24 (-) Amgen 129,1 - 1,2 %

25 (-) LEO Pharma AS 111,4 - 1,0 %

Aggregate sales top 25 companies 8 901,4 - 81,9 %

Aggregate sales all companies 10 866,1 2,9 % 100,0 %

Source: LMI/Farmastat* Parallell importers


1.08 The top 25 medicines on the Norwegian market in terms of sales value

Rank 2006(2005) Medicine

Sales 2006PPP, NOKmill.

Salesgrowth

Share oftotal sales Area of application

1 (1) Enbrel 340,9 3,46 % 3,1 % Rheumatoid arthritis

2 (5) Remicade 245,8 24,99 % 2,3 % Rheumatoid arthritis

3 (4) Seretide 242,3 -4,31 % 2,2 % Asthma

4 (2) Lipitor 167,2 -29,07 % 1,5 % High cholesterol

5 (8) Humira 159,3 26,47 % 1,5% Rheumatoid arthritis

6 (6) SymbicortTurbuhaler 137,0 10,43% 1,3 % Asthma

7 (7) Zyprexa 130,1 6,93 % 1,2 % Schizophrenia

8 (11) Cipralex 115,8 17,97 % 1,1 % Depression

9 (9) Selo-Zok 101,2 -5,91 % 0,9 % High blood pressure

10 (14) Paracet 97,5 15,62 % 0,9 % Pain

11 Nexium 87,3 63,43% 0,8 % Gastric ulcer

12 (18) Atacand 82,9 83,59 % 0,8 % High blood pressure

13 (17) Cozaar 80,3 5,14 % 0,7 % High blood pressure

14 (15) Lamictal 80,3 -4,58 % 0,7 % Epilepsy

15 (22) Otrivin 79,8 11,67 % 0,7 % Nasal congestion

16 (-) Mabthera 78,1 17,81 % 0,7 % Cancer andRheumatoid arthritis

17 (19) Cozaar Comp 77,1 2,04 % 0,7 % High blood pressure

18 (16) Insulatard 76,0 -3,56 % 0,7 % Diabetes

19 (24) Herceptin 75,5 13,08 % 0,7 % Cancer

20 (20) Plavix 74,3 -0,06 % 0,7 % Thrombosis

21 (-) Ibux 73,6 16,86 % 0,7 % Pain

22 (22) Rebif 73,5 4,08 % 0,7 % Multiple sclerosis

23 (25) Singulair 71,7 7,63 % 0,7 % Asthma

24 NexiumFarmagon 70,3 -62,52 % 0,6 % Gastric ulcer

25 (-) Coaprovel 66,0 24,52 % 0,6 % High blood pressure

Aggregate sales top 25 medicines 2 883,8 26,6 %

Aggregate sales all medicines 10 866,1 2,9 % 100,0 %

Source: LMI/FarmastatParalell import is not included. The growth rate for some products willreflect variations in the splitbetween direct and paralell imports.


1.09 The top 25 active ingredients as measured by defined daily doses (DDD)

Rank2006(2005) Active ingredient

Name oforiginalmedicine

SalesDDD/1000inhab./

Growth06-07DDD Area of application

1 (1) Simvastatin Zocor 110,2 28,6 % High cholesterol

2 (3) Acetylsalicylic acid Albyl-E 67,9 5,5 % Thrombosis

3 (2) Natriumfluorid - 67,6 -5,1 % Caries

4 (4) Atorvastatin Lipitor 49,5 -3,5 % High cholesterol

5 (5) Levonorgestrel - 37,3 8,3 % Contraception

6 (6) Ascorbic acid - 33,7 3,4 % Vitamin deficiency

7 (7) Zopiklon Imovane 32,8 5,2 % Insomnia

8 (8) Amlodipin Norvasc 32,0 5,7 % High blood pressure

9 (10) Cetirizin - 30,2 17,1 % Allergy

10 (9) Paracetamol - 28,4 12,0 % Pain

11* Xylometazolin Otrivin 27,8 - Nasal congestion

12 (12) Ramipril Triatec 25,2 6,0 % High blood pressure

13 (11) Metoprolol Selo-Zok 25,1 4,7 % High blood pressure

14 (13) Vitamin B complex - 23,3 3,7 % Vitamin deficiency

15 (15) Thyroxin - 22,4 4,9 % Hypothyreosis

16 (14) Furosemid Lasix Retard 20,7 -4,9 % High blood pressure

17 (20) Escitalopram Cipralex 16,5 27,6 % Depression

18 (18) Ibuprofen - 16,4 18,7 % Pain

19 (21) Kandesartan Atacand 15,2 17,1 % High blood pressure

20 (24) Drospirenon and oestrogen Yasmin 14,5 15,2 % Contraception

21 (17) Esomeprazol Nexium 13,9 -14,8 % Gastric ulcer

22 (16) Levonorgestrel and oestrogenTrinetta 12,9 - Contraception

23 (22) Codein, combinations - 12,8 -0,5% Pain

24 (25) Losartan and diuretic Cozaar Comp 12,7 3,2 % High blood pressure

25 (23) Enalapril Renitac 12,6 -1,7 % High blood pressure

Sum 761,5 -

Total sales 1 595,0 4,7 %

Share of total market 47,8 % -

Figures from2007 Source: LMI/Farmastat

*Market leader given for some active ingredients


1.10 The split of sales within the distribution chain

V.A.T.20,0%

Pharmacy15,3%

Wholesaler8,5%

Manufacturer56,2%

Source: LMI/Farmastat Covers sales through pharmaciesEstimate for 2007


1.11 Market share og generics (DDD)

0%

5%

10%

15%

20%

25%

30%

35%

40%

20072006200520042003200220012000

37,2%35,4%

31,8%

27,8%

24,0% 23,6% 23,3%25,1%

Sha

reof

tota

lsal

es

Year



1.12 Generics` share of the generics interchangeable market

0%

10%

20%

30%

40%

50%

60%

70%

80%

Value PPPDDD

2007200620052004

Sha

re

Year

Source: LMI/FarmastatExcluding Parallell imported medicines

Figures in PPP/DDD

31,0%

47,6%

30,5%

54,2%

46,2%

70,8%

46,4%

72,3%


1.13 Market share for parallel imported medicines

Per

cent


0%

1%

2%

3%

4%

5%

6%

7%

8%

2007200620052004200320022001200019991998199719961995

År

0,2%

4,3%

5,9%

6,9%

6,2%

6,6%6,3%

5,1%

7,7%

6,6%

7,0%

1,4%

3,4%


1.14 Market share for Wholesalers

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

50%

Apokjeden distribusjon AS - Tamro OY/Phoenix group

Holtung AS - Alliance UnichemPLC

NMD Grossisthandel AS - Celesio AG

200720062005200420032002Year


48,5%

15,0%

36,6%

45,3%

18,9%

35,7%

44,5%

35,2%

20,2%

45,3%

20,0%

34,8%

45,6%

20,1%

34,3%

46,4%

20,0%

33,5%


1.15 Pharmacy chain market share

Hospital pharmacies20,1%

Other pharmacies3,6%

Vitusapotek/Ditt Apotek24,3% Apotek 1

33,8%

Alliance apotekene18,1%



1.16 Pharmacy chain market share, excl. hospital pharmacies

Other pharmacies4,5%Vitusapotek/Ditt Apotek

30,4%

Apotek 142,4%

Alliance apotekene22,7%



1.17 Number of inhabitants per pharmacy in Europe

0 2 000 4 000 6 000 8 000 10 000 12 000 14 000 16 000 18 000 20 000

DenmarkSweden

NetherlandsNorwaySloveniaAustriaFinland

HungaryUnited Kingdom

SwitzerlandSlovakia

Czech RepublicPortugal

GermanyItaly

PolandIrelandFrance

LithuaniaSpain

BelgiumGreece 1 100

2016

2117

2302

2669

3050

3050

3330

3 800

3 800

3 930

4 036

4 435

4800

4886

6 727

6 888

7 292

8 115

9400

9 543

17 386

Figures from2006 Source: AESGP

Inhabitants per pharmacy


1.18 Pharmaceutical consumption (DDD) in the Nordic countries

1 000

1 200

1 400

1 600

1 800

2 000

Nordic averageNorwaySwedenFinlandDenmark

20072006200520042003

DD

Dpe

r10

00

inha

bita

nts

perda

y

Source: IMS Health

1 444

1 504 1 559

1 606

1 674

1 436

1 490

1 586

1 565

1 637

1 141

1 200

1 278

1 368

1 446

1 7191 765

1 813

1 871

1 932

1 2711 320

1 3601 410

1 474

Year


1.19 Leading pharmaceutical brands on the global market

Medicine nameRank 2006 (2005) Area of application

Sales US$Billion Growth %

1 (1) Lipitor High cholesterol 13,6 4,2 %

2 (3) Nexium Gastric ulcer and reflux 6,7 16,9 %

7 (9) Seretide (Advair) Asthma and COPD 6,3 10,3 %

4 (2) Plavix Prevention of cardovascular events 5,8 -3,4 %

5 (6) Norvasc High blood pressure 5,0 -0,5 %

6 (-) Aranesp Anemia 5,0 35,6 %

7 (7) Zyprexa Schizophrenia 4,7 -0,4 %

8 (-) Risperdal Psychosis and behavioural disorders 4,6 12,3 %

9 (-) Enbrel Rheumatic diseases and skin diseases 4,5 18,4 %

10 (10) Efexor Depression 4,0 2,7 %

Aggregate top 10 medicines 60,0 8,0 %

Aggregate all medicines 643,0 7,0 %

Source: IMS Health Data from 2006Figures in ex-factory prices


1.20 The Norwegian medicines market in relation to Europe

Country, Rank 2005 Sales million Euro, 2005 Share

1 Germany 24 846 19,2 %

2 France 23 838 18,4 %

3 Italy 15 749 12,2 %

4 UK 15 569 12,0 %

5 Spain 11 332 8,7 %

6 Greece 3 821 3,0 %

7 The Netherlands 3 795 2,9 %

8 Belgium 3 657 2,8 %

9 Portugal 3 105 2,4 %

10 Switzerland 2 709 2,1 %

11 Sweden 2 673 2,1 %

12 Austria 2 411 1,9 %

13 Finland 1 740 1,3 %

14 Denmark 1 536 1,2 %

15 Ireland 1 514 1,2 %

16 Norway 1 304 1,0 %

Aggregate 129 515 100,0 %

Source: EFPIA Figures in ex-factory prices or PPP


1.21 Leading pharmaceutical companies on the global market


2.01 Changes in prices of medicines and general inflation

-6%

-5%

-4%

-3%

-2%

-1%

0%

1%

2%

3%

4%

Medicines

Consumer Price Index

20072006200520042003200220012000

Sources: Statistics Norway and LMI/Farmastat

Pric

ech

ange

%

Year

0,8%

2,3%

1,6%

0,4%

2,5%

1,3%

3,0%3,1%

-1,6%

-4,0%

-2,3%

0,2%

-5,3%

-0,7%

-2,0%-2,3%


2.02 Public spending on reimbursable prescription medicines

NO

KM

illio

n

Source: NAV, Ministry of Health andCare Services, LMI

Figures for 2007 and 2008 are estimates

Year

Figures in mill. NOK, 2007-currency

0

2 000

4 000

6 000

8 000

10 000

12 000

200820072006200520042003200220012000199919981997

8 4208 211

8 591

9 2519 658

8 7688 541

7 607

7 0546 573

6 207

5 644


2.03 Payment for pharmaceutical consumption

Non prescription medicines11,6%Patient co-payment

6,4%

Prescription medicines(non-reimbursable)12,1%

Hospitals16,5%

Other public financing of prescription medicines1,6%

National Insurance Administration(reimburable medicines)51,8%

Sources: NAV, Norwegian Pharmacy Association,Statistics Norway, LMI/Farmastat

Figures from2006The figure is based on data from multiplesources, which resaults in some uncertainty.


2.04 Public health expenditure per inhabitant

0

5 000

10 000

15 000

20 000

25 000

30 000

35 000

Other Health Care expenditure Medicines Hospital services

2006200520042003200220012000

14 377

19 383 19 061 18 747 19 126 19 319 20 201

1 949

2 046 2 302 2 375 2 566 2 5802 590

7 351

3 4975 681 7 283

7 6908 449

8 611

Year

NO

Kper

inha

bita

nt

Sources: Statistics Norway, NAV 2006-currency

31 402

23 67724 925

27 04428 404

29 38230 348


2.05 Public spending on health care and medicines

YearGDP

NOK mill

Public spendingon health care

Public spendingon medicines % of public

spending onhealt careNOK mill % of GDP NOK mill % av GDP

2000 1 653 197 106 024 6,4 % 8 726 0,5 % 8,2 %

2001 1 664 806 111 614 6,7 % 9 161 0,6 % 8,2 %

2002 1 638 739 121 101 7,4 % 10 309 0,6 % 8,5 %

2003 1 663 729 127 195 7,6 % 10 634 0,6 % 8,4 %

2004 1 811 461 131 573 7,3 % 11 492 0,6 % 8,7 %

2005 1 983 819 135 899 6,9 % 11 554 0,6 % 8,5 %

2006 2 156 000 140 618 6,5 % 11 597 0,5 % 8,2 %

Figures in 2006 currencySources: Statistics Norway, NAV and LMI/Farmastat


2.06 Expenditure on medicines in the private and public sector

0

2 000

4 000

6 000

8 000

10 000

12 000

14 000

16 000

18 000

Private shareNational InsuranceHospitals

2006200520042003200220012000199919981997

Year

NO

Km

illio

n

Fixed prices, 2006-currencySources: Statistics Norway, NationalInsurance Administration and LMI/Farmastat

1584 1633 1381 1451 1430 1 574 1688 1911 20492 736

5752 6 290 65167275 7 731

8 734 89469581 9505

8861

33393656

44203999

4597

48804602

4826 4917 4803


2.07 Daily costs for the 25 most commonly used medicines


2.08 The consumer`s medicine expenses compared to other expenses

0 5 000 10 000 15 000 20 000

Pets

Flowers and gardening

Medicines

Non-alcoholic beverages

Newspapers and Magazines

Tobacco

Alcoholic beverages

Holiday trips

Tele services

Personal care

Restaurant

Clothes

Purchase of car

Food 15 826

13 827

7 157

4 752

3 345

3 206

3 049

2 795

1 555

1 376

1 308

1 281

1 114

717

Source: StatisticsNorway Average annual figures 2004-2006

NOK per inhabitant


2.09 National Insurance expenditure

Unemployment benefitsProfessional rehabilitationRetirement pensionDisability benefitsBasic and supplementary benefits, various aidsSickness and birth benefitsHealth care excl. medicinesSocial benefitsMedicinesMedical rehabilitationAdministrationOther Payments

Source: NAV

5,0%

37,9%

20,2%

3,2%

15,6%

4,2%

2,7%

1,3%0,1%

2,7%

3,7%


2.10 Health care expenditure

2001 2002 2003 2004 2005 2006

Total health care expenditure,nominal values

135 266 150 029 159 572 168 237 176 031 186 396

Total public health careexpenditure, nominal values

112 000 124 351 132 711 139 666 146 106 154 709

Publicly financed share of totalhealth care expenditure

83 % 83 % 83 % 83 % 83 % 83 %

Total private expenditure,nominal values

23 266 25 678 26 861 28 571 29 925 31 687

Publicly financed share of totalhealth care expenditure

17 % 17 % 17 % 17 % 17 % 17 %

Total expenditure medicines,nominal values

12 700 14 200 14 600 15 700 16 100 16 400

Medicines as share of totalhealth care expenditure

9,4 % 9,5 % 9,1 % 9,3 % 9,1 % 8,8 %

Total health care expenditure,fixed 2006-currency

146 466 160 385 166 504 174 770 180 007 186 396

Annual growth in health careexpenditure, fixed 2006-currency

5,3 % 9,5 % 3,8 % 5,0 % 3,0 % 3,5 %

Public health care expenditure asshare of total public expenditure

16,4 % 16,8 % 16,8 % 17,0 % 17,3 % 17,1 %

NOK mill. or percent

Sources: Statistics Norway/LMI/Farmastat


2.11 Intenational price index for medicines

90

95

100

105

110

115

120

125

Irelan

d

Switz

erlan

d

Denmar

k

German

y

Nethe

rland

s

UK

Swed

en

Portu

gal

AustriaItaly

Finla

nd

Norway

Fran

ce

Belgi

um

Greec

e

Spain

Inde

x,N

orw

ay=1

00

Source: LMI Data as of autumn 2005

119,8

116,8116,5

115,8

109,4108,5

107,0

104,4

103,1102,5

101,0100,0

99,0

97,897,5

92,0


2.12 VAT on medicines and other goods and services in Europe

CountryStandardVAT %

VAT on medicines %

VAT on food %PrescriptionNon-prescrip-

tion (OTC)

Denmark 25,0 25,0 25,0 25,0

Norway 25,0 25,0 25,0 14,0

Germany 19,0 19,0 19,0 7,0

Italy 20,0 10,0 10,0 4,0-10,0

Finland 22,0 8,0 8,0 17,0

Greece 19,0 9,0 9,0 9,0

Belgium 21,0 6,0 6,0 6,0

Netherlands 19,0 6,0 6,0 6,0

Portugal 21,0 5,0 5,0 5,0 - 12,0

Spain 16,0 4,0 4,0 4,0-7,0

France (1) 19,6 2,1-5,5 2,1-5,5 5,5

Switzerland 7,6 2,4 2,4 2,4

Ireland (2) 21,0 0,0 - 21,0 0,0 - 21,0 0,0

Austria 20,0 20,0 20,0 10,0

Sweden 25,0 0,0 25,0 12,0

UK (3) 17,5 0,0 17,5 0,0-17,5


2.13 Market growth for medicines in the Nordic countries

0%

2%

4%

6%

8%

10%

12%

FinlandNorwaySwedenDenmarkAverage for theNordic Countries

Source: IMS Health Growth 2006-2007

7,2%

3,5%

6,9%

10,2%

7,1%

Sal

esgr

owth

2006-2

007

in %


2.14 Copayment for reimbursable medicines

0 %

10 %

20 %

30 %

40 %

50 %

60 %

70 %

80 %

90 %

100 %

Costs paid by the patient Costs paid by compulsory health insurance systemsSl

oven

ia

Den

mar

k

Finl

and

Portu

gal

Swed

en

Hun

gary

Belg

ium

Aust

ria

Gre

ece

Irela

nd

Switz

erla

nd

Ger

man

y

Nor

way

Spai

n

UK

Fran

ce

Italy

Net

herla

nds

Data from2004 Source: EFPIA

99,7

%

95,2

%

94,7

%

94,0

%

92,9

%

90,

8 %

90,

1 %

90,

0 %

90,

0 %

84,8

%

83,5

%

83,3

%

80,

1 %

74,0

%

69,4

%

65,9

%

60,

1 %

56,3

%

0,3

%

4,8

%

5,3

%

6,0

%

7,1

%

9,2

%

9,9

%

10,0

%

10,0

%

15,2

%

16,5

%

16,7

%

19,9

%

26,0

%

30,6

%

34,1

%

39,9

%

43,7

%


2.15 Spending on medicines as share of spending on health care in the OECD

0 % 5 % 10 % 15 % 20 % 25 %

Denmark

Norway

Switzerland

Ireland

Netherlands *

Austria

Sweden

United States

Germany

Finland

France

Canada

J apan **

Italy

Portugal

Spain 22,8 %

21,6 %

20,1 %

19,0 %

17,8 %

16,4 %

16,3 %

15,2 %

12,4 %

12,0 %

11,6 %

11,5 %

10,9 %

10,4 %

9,1 %

8,9 %

Figures from2005*Figures from2002**Figures from2004 Source: OECD

Percent


3.01 Sales on non-prescription medicines

0

100

200

300

400

500

600

700

800

900

1 000

20072006200520042003200220012000

Year

NO

Km

ill.P

PP

892853

833834810802

761737

Source: LMI/Farmastat Figures in PPP, 2007-currency


3.02 Non-prescription medicines, share of total market value (PRP) and DDD

0%

5%

10%

15%

20%

25%

DDDPRP

20072006200520042003200220012000


Year

Per

cent

21,2%20,6%

19,8% 19,6% 19,8%19,1%

18,1%

17,2%

12,0%11,7%11,4%11,6%11,5%

12,7%13,4%

14,0%


3.03 The top 25 non-prescription medicines an terms of sales value


Sales PPP in2007, NOK mill.

Change in salesfrom 2006

Example on area ofapplication

1 (1) Paracet 82,3 12,0 % Pain

1 (2) Otrivin 80,0 11,8 % Nasal congestion

3 (3) Ibux 64,5 16,2 % Pain

4 (4) Nicorette 54,7 9,8 % Smoking cessation

5 (5) Nicotinell 44,7 3,7 % Smoking cessation

6 (8) Pepcidduo 21,6 18,9 % Reflux

7 (6) Flux 21,0 -4,9 % Caries prevention

8 (7) Canesten 19,5 -4,1 % Fungal infections

9 (10) Livostin 15,0 10,3 % Allergy

10 (9) Zyrtec 15,0 -4,4 % Allergy

11 (13) Nycoplus C-Vitamin 11,9 5,3 % Vitamin supplement

12 (12) Rhinox 11,2 -2,7 % Nasal congestion

13 (20) Duphalac 10,7 21,4 % Constipation

14 (18) Solvipect 10,1 11,7 % Coughs

15 (11) Pinex 10,0 -15,4 % Pain

16 (14) Ibumetin 9,8 -3,8 % Nasal congestion

17 (19) Microlax 9,4 4,4 % Constipation

18 (15) Phosphoral 9,2 -4,1 % Intestine drain

19 (-) Bisolvon 9,1 34,9 % Airway diseases

20 (21) Norlevo 8,7 4,7 %Emergency contra-ception

21 (17) Minifom 8,6 -8,0 % Gastric gas

22 (25) Kaleorid 8,4 11,6 % Potassium supplement

23 (16) Zymelin 8,2 -13,6 % Nasal congestion

24 (-) Corsodyl 7,7 6,9 %Prevention of mouthinfections

25 (22) Ovesterin 7,6 -5,2 % Oestrogen deficiency

Sum top 25 559

Total sales 895 5,8 %

Share of total sales 62,4 %

Figures from 2007 Source: LMI/Farmastat


3.04 Non-prescription medicines sales by selected therapy groups (ATC)

NOK mill. Growth 06-07

Analgesics 206,5 8,1 %

Gastrointestinals 144,7 4,3 %

Coughs and pneumonia 134,6 7,3 %

Smoking cessation 99,5 7,0 %

Dermatologicals 88,3 9,9 %

Vitamins and minerals 42,4 -1,8 %

Allergy 31,9 -5,7 %

Hormones 16,7 -0,5 %

Sum 709,1 5,8 %

Total sales OTC 892,0 5,8 %

Figures (PPP) from 2007 Source: LMI/Farmastat


3.05 The top 10 pharmaceutical companies in the non-prescription medicines market

Rank 2006(2005) Company

Total sales 2006PPP, NOK mill. Sales growth Market share

1 (1) Weifa AS 166,3 9,6 % 18,6 %

2 (2) Novartis Norge AS 156,2 8,8 % 17,5 %

3 (3) Nycomed Pharma AS 107,6 -0,3 % 12,0 %

4 (-) McNeil 87,1 25,6 % 9,7 %

5 (5) Alpharma As 51,6 -8,0 % 5,8 %

6 (6) J anssen-Cilag AS 36,9 13,1 % 4,1 %

7 (-) Bayer Schering Pharma 24,0 -3,1 % 2,7 %

8 (10) Solvay Pharma AS 22,0 5,4 % 2,5 %

9 (9) GlaxoSmithKline AS 20,0 -1,6 % 2,2 %

10 (7) AstraZeneca SA 18,7 0,5 % 2,1 %

Aggregate sales top 10 compa -nies

690,4 77,1 %

Aggregate sales allnon-prescription medicines

895,0 5,8 % 100,0 %



3.06 Non-prescription medicines, market share (PRP) in selected countries


3.07 Split by category of general sales outlets for non-prescription medicines except pharmacies

Other192; 3,2%

Gas stations1 118; 18,4%

Kiosk900; 14,8%

Health food stores372; 6,1%

Groceries3 493; 57,5%

Kilde: Norwegian Medicines Agency Number of outlets as of December 2007


3.08 Segmentation of sales for non-prescription medicines

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

200720062005

Nikotin(N07BA01)

Xylometazolin(R01AA07)

Paracetamol(N02BE01)

Fenazon-koffein(N02BB51)

Ibuprofen(M01AE01)

Numbers measured as DDD

Data fromthe first nine months in 2005 and 2006 for the most sold active substances

Denotes sales of medicines sold both in and outside of pharmacies

Source: Norwegian Institute of public health

33%37%38%

43%

38%

46%50%

13%17%

13%

39%

33%

14%15%14%

Active Substance

Sha

reou

tsid

eph

arm

acie

s


4.01 The top 10 veterinary medicines for aquaculture in terms of sales value

# Medicine Sales 2007, mill. NOK Area of application

1 Pentium forte 84,4 Fish vaccine

2 Alphaject 6-2 84,1 Fish vaccine

3 Norvax minova 6 Vet 69,2 Fish vaccine

4 Alpha max vet 36,9 Treatment against sea lice

5 Norvax compact PD Vet 30,8 Fish vaccine

6 Alphaject 5-3 Vet 13,7 Fish vaccine

7 Norvax Compact PD 6 Vet 11,9 Fish vaccine

8 Betamax Vet 10,4 Treatment against sea lice

9 Benzoak Vet 79,5 Sedation

10 Aquavac IPN Vet 60,5 Fish vaccine


Figures measured in recommended retail prices to the customer


4.02 The top 10 veterinary medicines for mammels in terms of sales value

# MedicineSales 2007PPP, mill. NOK Area of application Animal segment

1 Panacur Vet 9,5 Worm treatmentBoth pets and animalsfor production

2 Nobivac DHPPI Vet 8,5 Vaccine Pets

3 Metacam Vet 8,5 Treatment of painBoth pets and animalsfor production

4 Rimadyl Vet 7,1 Treatment of pain Pets

5 Synolux Vet 6,0 Bacterial infections Pets

6 Penovet 5,3 Bacterial infectionsBoth pets and animalsfor production

7 Exspot pour on Vet 5,1 Parasite treatment Pets

8 Ivomec Vet 5,0Worm and mite treat-ment

Animals for production

9 Banmint Vet 5,0 Worm treatment Pets

10 Streptocil Forte Vet 4,6 Bacterial infections Animals for production



4.03 the top 5 companies within aquaculture

# Company Sales 2006, mill. NOK

1 Pharmaq 142,8

2 Intervet Norbio 120,6

3 Scan Vacc 90,2

4 Vericore 10,8

5 Europharm 7,9


4.04 The top 10 companies within veterinary medicines excluding aquaculture

# Company Sales 2006, mill. NOK

1 Orion Pharma 42,7

2 Intervet 40,8

3 Schering-Plough 30,9

4 Boering Vet 26,4

5 Bayer Schering 16,2

6 Meral 15,8

7 Scanvet 13,5

8 VetXX 5

9 Novartis 4,6

10 Kela Laborator 2,2

Source: LMI/FarmastatFigures measured in recommended retail prices to the customer


5.01 The investment of the pharmaceutical industry in research and development

0

200

400

600

800

1 000

1 200

20062005200420032002200120001999199819971996

NO

KM

illio

n

Year

985943

864

1 047

885

818

693

812780

724706

Source: LMI Fixed 2006-currency


5.02 Investments in research and development, percentage of sales

0%

2%

4%

6%

8%

10%

12%

14%

2006200520042003200220012000199919981997

Per

cent

Year

Source: LMI

11,1%11,6%

11,1%

9,0%9,6% 9,5%

11,2%

8,7%

9,6%10,0%


5.03 Submitted clinical trials

0

50

100

150

200

250

Total number of applications to The NorwegianMedicines AgencyNumber of trials submitted by LMI’s members

200720062005200420032002Year

Sub

mitt

edcl

inic

altria

ls


101 113 106 118 86

187 201 224 194 173 179


5.04 Ongoing clinical trials performed by the pharmaceutical industry

Phase of study Number of trials Number of centres Number of patients

Phase 1 6 6 16

Phase 2 37 138 3 355

Phase 3 126 706 9 123

Phase 4 40 222 1 624

Total 209 1072 14 118

Source: LMI Data from 2006


5.05 Industry initiated trials

0

50

100

150

200

250

300

TotalPhase 4Phase 3Phase 2Phase 1

20062005200420032002

Year

Num

berof

prot

ocol

s

Source: LMI

209

273

233

206

182

126

172159

149

124

4053

353029

3747

37

2627 61112


5.06 Norway`s imports and exports of medicines

0

1 000

2 000

3 000

4 000

5 000

6 000

7 000

8 000

9 000

10 000

Exports

Imports

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

Year

NO

Km

illio

n

Source: Statistics Norway/LMI


5.07 Number of employees in the pharmaceutical industry in Norway

0

500

1 000

1 500

2 000

2 500

3 000

3 500

4 000

4 500

5 000

20072006200520042003200220012000

4 402 4 4474 572 4 603 4 571 4 564

4 691 4 670

Em

ploy

ees

Year

Source: LMI


5.08 Employees in companies with production facilities in Norway


Sales 2006PPP, NOKmill.

Salesgrowth

Share oftotal sales Area of application

1 (1) Enbrel 340,9 3,46 % 3,1 % Rheumatoid arthritis

2 (5) Remicade 245,8 24,99 % 2,3 % Rheumatoid arthritis

3 (4) Seretide 242,3 -4,31 % 2,2 % Asthma

4 (2) Lipitor 167,2 -29,07 % 1,5 % High cholesterol

5 (8) Humira 159,3 26,47 % 1,5% Rheumatoid arthritis

6 (6) SymbicortTurbuhaler 137,0 10,43% 1,3 % Asthma

7 (7) Zyprexa 130,1 6,93 % 1,2 % Schizophrenia

8 (11) Cipralex 115,8 17,97 % 1,1 % Depression

9 (9) Selo-Zok 101,2 -5,91 % 0,9 % High blood pressure

10 (14) Paracet 97,5 15,62 % 0,9 % Pain

11 Nexium 87,3 63,43% 0,8 % Gastric ulcer

12 (18) Atacand 82,9 83,59 % 0,8 % High blood pressure

13 (17) Cozaar 80,3 5,14 % 0,7 % High blood pressure

14 (15) Lamictal 80,3 -4,58 % 0,7 % Epilepsy

15 (22) Otrivin 79,8 11,67 % 0,7 % Nasal congestion

16 (-) Mabthera 78,1 17,81 % 0,7 % Cancer andRheumatoid arthritis

17 (19) Cozaar Comp 77,1 2,04 % 0,7 % High blood pressure

18 (16) Insulatard 76,0 -3,56 % 0,7 % Diabetes

19 (24) Herceptin 75,5 13,08 % 0,7 % Cancer

20 (20) Plavix 74,3 -0,06 % 0,7 % Thrombosis

21 (-) Ibux 73,6 16,86 % 0,7 % Pain

22 (22) Rebif 73,5 4,08 % 0,7 % Multiple sclerosis

23 (25) Singulair 71,7 7,63 % 0,7 % Asthma

24 NexiumFarmagon 70,3 -62,52 % 0,6 % Gastric ulcer

25 (-) Coaprovel 66,0 24,52 % 0,6 % High blood pressure

Aggregate sales top 25 medicines 2 883,8 26,6 %

Aggregate sales all medicines 10 866,1 2,9 % 100,0 %

Source: LMI/FarmastatParalell import is not included. The growth rate for some products willreflect variations in the splitbetween direct and paralell imports.

facts and figures 2008

Documents